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. Introduction
Ageing has been deﬁned as the time-dependent decline of func-
ional capacity and stress resistance, associated with increased
isk of morbidity and mortality. Ageing is a process that affects
ost if not all tissues and organs of the body. Moreover, cross-talk
an occur between multiple physiological systems, e.g. metabolic
ystems may  inﬂuence the ageing of the immune system. The
echanisms underlying the ageing process are beginning to be
nravelled at the molecular level (López-Otín et al., 2013), yet there
s clear evidence that the rate of ageing differs signiﬁcantly between
embers of the same animal species, including humans. In other
ords, the “biological age” may  differ from the chronological age.
The classical quantitative assessment of “the rate of ageing”
elies on the analysis of mortality curves (Gompertz function) of
opulations. In other words, individuals have to be followed up
ntil the end of their lives in order to determine their “biologi-
al age” at any time point during life. Therefore, at the level of
 living individual, a reliable of assessment of the state of ageing, i.e.
he state of the above-mentioned functional decline, and a predic-
ion of the risk of the onset of morbidity and the residual individual
ife expectancy are not possible with this method.
One strategy to solve this problem is the identiﬁcation of (an)
ge-related change(s) in body function or composition that could
erve as a measure of “biological” age and predict the future onset of
ge-related diseases and/or residual lifetime more accurately than
hronological age. Such parameters are termed “biomarkers of age-
ng” (Baker and Sprott, 1988). This term has been coined in analogy
o biomarkers of speciﬁc chronic diseases, such as HIV infection, or
iomarkers of exposure to toxins.
The American Federation for Aging Research has proposed the
ollowing criteria for a biomarker of ageing:
. It must predict the rate of ageing. In other words, it would tell
exactly where a person is in their total life span. It must be a
better predictor of life span than chronological age.
. It must monitor a basic process that underlies the ageing process,
not the effects of disease.
. It must be able to be tested repeatedly without harming the
person, for example, a blood test or an imaging technique.
. It must be something that works in humans and in laboratory
animals, such as mice. This is so that it can be tested in lab animals
before being validated in humans.
The fourth of the above criteria may, however, be questioned
s there are certainly some parameters whose importance for the
Fig. 1. Schematic representation of the managend Development 151 (2015) 2–12 3
ageing process may  differ between mammalian species. One exam-
ple would be telomere shortening in humans and in laboratory
mice: While in human somatic tissues telomere shortening can
readily be detected, this is not the case in wild-type laboratory
mouse strains owing to their much greater overall length of telom-
eres. Therefore eliminating some candidate parameters just based
on their lack of relevance in some model systems may  lead to
an exclusion of parameters that are potentially interesting for the
human system.
It should be noted that many candidate biomarkers of human
ageing have been proposed in the scientiﬁc literature but in all
cases their variability in cross-sectional studies is considerable,
and therefore no single measurement has proven to serve a useful
marker to determine, on its own, biological age. A plausible reason
for this is the intrinsic multi-causal (Holliday, 2006) and multi-
system nature of the ageing process. MARK-AGE was a large-scale
integrated project supported by the European Commission. The
major aim of this project was to conduct a population study com-
prising about 3200 subjects in order to identify a set of biomarkers
of ageing which, as a combination of parameters with appropriate
weighting, would measure biological age better than any marker
in isolation.
2. MARK-AGE consortium
In order to tackle the scientiﬁc problem of establishing power-
ful biomarkers of human ageing, the MARK-AGE consortium, which
consisted of 26 Partners comprising 21 non-proﬁt organisations
(universities and public research institutes), 3 small and medium
sized enterprises (SMEs), and 2 large companies, was  formed. The
scientiﬁc groups involved are at the forefront in the ﬁeld of ageing
research, and some Partners are international leaders even in wider
ﬁelds such as Genetics. The MARK-AGE consortium was charac-
terised by a high degree of interdisciplinarity: The array of expertise
ranged from Geriatrics, Epidemiology and Human Genetics to Clin-
ical Chemistry, Biochemistry, Cell Biology, Immunology, Molecular
Genetics, Bioinformatics and Mathematical Modelling. Such a level
of interdisciplinarity is essential for the success of a project of this
large scale. The lead researchers are the authors on this document.
3. The MARK-AGE strategyIn the Large-Scale Integrating Project MARK-AGE, the Partners
proposed to perform a comprehensive and coherent Europe-
wide population study aiming at the identiﬁcation of powerful
biomarkers of human ageing across a range of physiological
ment structure of the MARK-AGE project.
4 A. Bürkle et al. / Mechanisms of Ageing a
Table  1
MARK-AGE work packages.
Work package number Work package title
1 Recruitment of probands and physiological
markers
2  DNA-based markers
3 Markers based on proteins and their
modiﬁcations
4 Immunological markers
5 Clinical chemistry, hormones and markers of
metabolism
6 Oxidative stress markers
7 Emergent biomarkers of ageing from model
systems and novel methodological approaches
8  Data analysis and bioinformatics
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• Body mass index.9  Dissemination and training
10  Project management and ethical issues
ystems. The study population comprised of about 3200 subjects
nd represented several different geographical regions of Europe.
he study population covered the age range of 35–74 years, as this
s the time span during which prophylaxis / intervention to counter
ge-related diseases may  be possible and promising. A wide range
f candidate biomarkers was tested, including (1) “classical” ones
or which data from several smaller studies have been published;
2) “new” ones, based on preliminary data obtained in small-scale
tudies, as well as (3) “novel” ones, based on recent research on
echanistic aspects of ageing, conducted by project Partners.
It is reasonable to assume that a combination of several
iomarkers will provide a much better tool to measure biologi-
al age than any single biomarker in isolation. It has to be taken
nto account, though, that not all biomarkers are of equal weight.
herefore averaging all possible candidate biomarkers may  not
ppropriate. A major task of this project was, therefore, to opti-
ise the weighting of the different markers, by using multi-variate
nalysis, with the aim of reducing variance and to derive a mathe-
atical formula that will yield a “biological age score”. It should be
entioned that work performed in the context of the “MacArthur
tudies of successful aging” on a cohort of 171 adults aged 70–79
ad already provided proof-of-concept by showing that an “allo-
tatic load score”, incorporating 10 biological markers, can be
redictive of mortality risk (Seeman et al., 1995).
The MARK-AGE project provided a systematic approach: The
onsortium established Standard Operating Procedures for the
ecruitment of subjects and processing of samples (see Moreno-
illanueva and Capri et al., this issue), as well as quality control
easures (Jansen et al., this issue). It was deemed essential to
ecruit a new population of subjects, since previous recruitment
fforts performed in many European countries neither have cov-
red the age range of interest nor have they provided the biological
aterials to be studied, including cryopreserved blood cells.
The activities within the MARK-AGE project were distributed in
ork Packages (Table 1)
.1. WP1: recruitment of subjects and assessment of physiological
arkers
Two large groups of subjects were recruited. After exclusion
f 138 hepatitis positive subjects, the ﬁrst group comprised of
262 randomly recruited age-stratiﬁed individuals from the gen-
ral population (RASIG) from several different geographical regions
f Europe. Equal numbers of men  and women were enrolled, com-
rising similar numbers of individuals in the following age classes:
5–39 yrs, 40–44 yrs, 45–49 yrs, 50–54 yrs, 55–59 yrs, 60–64 yrs,
5–69 yrs, 70–74 yrs. This group was thought to be display the
average population ageing rate”.nd Development 151 (2015) 2–12
The second group comprised of subjects born from a long-living
parent belonging to a family with long-living sibling(s), such as the
“90+ sibpairs” recruited within the framework of the EU Integrated
Project GEHA, and henceforth designated GEHA offspring (GO) (528
subjects). GO cover the age range of 55–74 years. According to data
from the recent literature, indicating that offspring of long-living
parents age in a “better” way than controls born from non long-
living parents, GO are predicted to age at a slower rate than the
average population.
Within the MARK-AGE project, the GO subjects were therefore
compared with their spouses, henceforth designated spouses of
GEHA offspring (SGO) (305 subjects). Systematic comparison of GO
and SGO cohorts should provide a unique opportunity for a ﬁrst val-
idation of the biomarkers identiﬁed in the cross-sectional study of
the RASIG subjects. It is expected that GO display a lower biological
age than SGO.
The project also took advantage of the fact that some relatively
rare ‘segmental progeroid syndromes’ present characteristics of
dramatically accelerated ageing and premature death from typi-
cal ageing-associated diseases. This is the case for subjects affected
by Down’s syndrome (DS) or Werner’s syndrome (WS). Due to the
(extreme) rarity of these syndromes, only a small number of DS
subjects were recruited, while biological material (serum, plasma,
urine and blood) from WS  patients was  stored in the MARK-AGE
biobank. The ageing process of DS and WS  subjects is being com-
pared with RASIG and GO/SGO subjects. It is expected that their
biomarkers indicate a higher biological age, and so this comparison
is expected to provide an additional validation for the biomarkers
identiﬁed in the cross-sectional analysis of RASIG.
In order to ascertain the biological and analytical robustness of
the measurements of candidate biomarkers, 97 donors from the
whole study population have been re-sampled within 3–6 months.
In such a short time period, no signiﬁcant change in the biological
age status of the subjects is expected; therefore an ideal biomarker
essentially should yield the same results.
Finally, a limited random sample of subjects was  followed-up in
a small longitudinal study, compatible with the time and budgetary
constraints of the project. We  re-tested 12% of the recruited sub-
jects RASIG, GO, SGO (389 subjects in total) after 3 years. It was
expected that those subjects whose biomarker proﬁle indicated
an advanced biological age at baseline should display a similar or
accelerated pattern at the 3-year follow-up, and vice versa for the
biologically younger individuals.
From all subjects enrolled, anthropometric, clinical and demo-
graphic data have been collected in a standardised fashion. Upon
written informed consent, the following set of information was
obtained by using a standardised questionnaire:
• Demographic information: family composition, marital status,
education, occupation, and housing conditions.
• Lifestyle: use of tobacco and alcohol, daily activities.
• Functional status: Activities of Daily Living (ADL) and Norton
Scale.
• Cognitive status: STROOP test, 15-picture learning test.
• Health status: present and past diseases, self-perceived health,
number and type of prescribed drugs.
• Mood: ZUNG depression scale.
A physical examination of all subjects comprised measurement
of the following “classical” candidate biomarkers:• Waist and hip circumference.
• Blood pressure at rest.
• Heart rate at rest.
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Lung function – forced expiratory volume in 1 s (FEV1).
Lung function – forced vital capacity (FVC).
Five-times chair standing.
Handgrip strength.
All subjects were asked to donate blood (55 ml)  by venipuncture
fter overnight fasting. The blood sample was processed to obtain
lasma, serum and peripheral blood mononuclear cells (PBMC).
BMC were cryopreserved and all the other components were
rozen down. Buccal mucosal cells were also collected (using a kit)
s well as spot urine samples (see Moreno-Villanueva and Capri
t al., this issue).
.2. WP  2: DNA-based markers
The integrity of the nuclear genome and the epigenome is of
ital importance for the proper function of cells, tissues and organs.
here is, however, a constant attack by exogenous and endogenous
ompounds and agents (including reactive oxygen species [ROS])
hat can damage DNA and/or disturb epigenetic regulation. Possible
onsequences are mutation and dysregulation of gene expression,
hich either can lead to cell death or cellular senescence or to
alignant transformation of the cells ultimately resulting in can-
er. Protection and maintenance systems have evolved that help
aintain a sustainable steady-state level of molecular damage, and
hese include DNA repair systems and DNA methyl transferases.
urthermore telomeric DNA undergoes attrition with each replica-
ion cycle and also as a consequence of DNA damage. A critical loss
f telomere repeat sequences has been shown to prevent further
ell proliferation and in some cell types induces cellular senescence.
Mitochondrial DNA is an especially vulnerable target for muta-
enesis, in view of the high local levels of endogenous ROS in
itochondria. Damage and mutation of mitochondrial DNA is
iewed as a major mechanism driving the ageing process (Niemi
t al., 2003; Wong et al., 2009; Altilia et al., 2012). Neverthe-
ess D-loop region contains level of heteroplasmy associated with
ongevity, as previously identiﬁed (Rose et al., 2007), suggesting
lso mtDNA variants- based mechanisms of protection (Raule et al.,
014). Further, APOE genotype, which is considered a gold stan-
ard for the genetics of longevity and was recently re-conﬁrmed
Deelen et al., 2014), was taken into account with the basic idea to
dentify possible subgroups of individuals with best or worst health
onditions (extreme phenotypes).
Our overarching hypothesis was that the presence of proﬁ-
ient systems to prevent/repair damage and mutation (Beneke and
urkle, 2007) to the nuclear genome (Reale et al., 2005; Caiafa and
ampieri, 2005; Zardo et al., 2002), including telomere shortening
Canela et al., 2007; Benetti et al., 2007; Flores et al., 2005; Gonzalo
t al., 2006), and to the mitochondrial genome (Bellizzi et al., 2006;
e Benedictis et al., 1999) should help retard the ageing process
n many if not all tissues. Therefore these cellular functions have a
otential to serve as biomarkers of ageing.
The following research tasks have speciﬁcally been addressed:
We have studied the maintenance of the epigenome by analysing
gene expression patterns in PBMC and cytosine methylation sta-
tus. DNA methylation was to be correlated with the possible
age-dependent expression level of some genes whose expression
has been associated with ageing or longevity.
The ageing-dependent decline of DNA repair was evaluated by
functional analysis of the repair of DNA strand breaks induced by
X-rays and in studies on cellular poly(ADP-ribosyl)ation capacity
and PARP-1 expression levels.
Attention was also directed towards telomere length, which is
being correlated with modiﬁcations of subtelomeric DNA methy-
lation pattern.nd Development 151 (2015) 2–12 5
• The question of an age-related accumulation of mutations in
mtDNA was to be addressed by quantifying the level of hetero-
plasmy. Special attention was  paid to heteroplasmy of the mtDNA
control region.
• Donors were stratiﬁed for their APOE genotype to correlate this
with the type of ageing, i.e. successful or unsuccessful ageing.
3.3. WP  3: markers based on proteins and their modiﬁcations
One important physiological posttranslational modiﬁcation of
secreted proteins is addition of N-linked oligosaccharides (N-
glycans). Since most N-glycans are on the outer surface of cellular
and secreted macromolecules, they can modulate or mediate a wide
variety of events in cell-cell and cell-matrix interactions crucial for
the development and function of complex multicellular organisms.
Because the biosynthesis of glycans is not controlled by interac-
tion with a template but depends on the complicated concerted
action of glycosyltransferases, the structures of glycans are much
more variable than those of proteins and nucleic acids, and they
can be easily altered by the physiological conditions of the cells.
Accordingly, studying age-related alterations of the glycans could
be relevant to understanding the complex physiological changes
in ageing individuals (Vanhooren et al., 2010). The objective of this
sub-task was to determine the changes in the blood N-glycome dur-
ing human ageing of healthy humans and to develop methodology
for proﬁling urine N-glycans (Vanhooren et al., 2007).
The apolipoprotein J/Clusterin (ApoJ/CLU) is a highly conserved
multifunctional glycoprotein. Amongst its multiple physiological
functions, this protein is a chaperone that stabilizes stressed pro-
teins in a folding-competent state. Previous work had shown that
ApoJ/CLU is associated with human ageing and with ageing of
human cells in vitro, and that its level is increased in patients with
type II diabetes, coronary heart disease, and myocardial infarction.
Therefore ApoJ/CLU may  represent a valuable ageing biomarker.
Non-enzymatic protein glycation is a common posttranslational
modiﬁcation of proteins in vivo, resulting from reactions between
glucose and amino groups on proteins; this process is termed “Mail-
lard reaction” and leads to the formation of Advanced Glycation
Endproducts (AGEs). During normal ageing, there is accumulation
of AGEs of long-lived proteins such as collagens and cartilage. AGEs,
either directly or through interactions with their receptors, are
involved in the pathophysiology of numerous age-related diseases
(Simm et al., 2014), such as cardiovascular and renal diseases and
neurodegeneration. However, in a cohort study on human ageing,
the correlation of AGEs with human age remained debatable. By
analysing overall parameters of AGEs as well as speciﬁc AGEs, it was
to be determined if these modiﬁcations correlate with age indepen-
dently of disease and if there are gender differences (Scheubel et al.,
2006; Simm et al., 2004).
It is well known that levels of oxidised proteins increase with
age, due to increased protein damage induced by ROS, decreased
elimination of oxidised protein (i.e. repair and degradation), or a
combination of the two. Since the proteasome is in charge of both
general protein turnover and the selective removal of oxidized pro-
tein, its fate during ageing has received considerable attention,
and evidence has been provided for an impairment of proteasome
function with age in different cellular systems (Chondrogianni and
Gonos, 2010; Baraibar and Friguet, 2013), including human PBMC
(Chondrogianni et al., 2003, 2005; Carrard et al., 2003; Friguet,
2006). Apart from to being degraded, certain oxidised proteins can
be repaired. However, repair is limited to the reversion of a few
oxidative modiﬁcations of sulphur-containing amino acids, such as
the reduction of methionine sulfoxide by the methionine sulfoxide
reductase (Msr) system. Msr  activity is known to be impaired dur-
ing ageing and replicative senescence. Therefore, the status of both
proteasome and Msrs A and B in human PBMC from the recruited
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onors of different ages was to be assessed. These parameters had
reviously been shown to be key players in oxidised protein degra-
ation and repair and to exhibit a declining activity with age (Picot
t al., 2004, 2007). These protein maintenance systems, viewed as
otential biomarkers of ageing, were to be monitored at the levels
f enzymatic activity, protein expression, and RNA expression.
The following research tasks have speciﬁcally been addressed:
Analysisof the N-glycomic changes in glycoproteins from blood
of all donors. Urine glycoprotein changes were to be studied in a
subset of subjects.
ApoJ/CLU levels in serum from all donors.
AGEs in plasma by ﬂuorescence spectroscopy and by immuno-
logical analysis of carboxy-methyllysine, pentosidine, arg-
pyrimidine and imidazolone.
Protein damage in blood at different levels, i.e. activities of pro-
teasome and methionine sulfoxide reductases in PBMC lysates;
RNA levels of representative proteasome subunits (catalytic and
regulatory) and methionine sulfoxide reductases A and B; and
protein levels of representative proteasome subunits and methi-
onine sulfoxide reductases A and B in PBMC lysates.
.4. WP  4: immunological markers
Thymic output is known to decline with age; furthermore the
ate of decline is dependent on gender, with greater thymic out-
ut for longer in females compared with males (Aspinall et al.,
007). Females often develop better immune responses than males,
hich may  relate to their longer lifespan. Within MARK-AGE, signal
oint T-cell receptor rearrangement excision circles (sjTREC) were
ssessed as a candidate biomarker of ageing and thymic involution,
y analysing sjTREC levels in individuals at various ages (Aspinall
t al., 2007).
A robust immunological memory is known to be a guarantor of
ealth in adults and in particular in elderly persons, while chronic
atent infections, such as CMV  infection, have been shown to be
ssociated with shorter life expectancy. Auto-immune responses
ay  also restrict the diversity of immune responsiveness to for-
ign antigens. We  therefore evaluated long-term and short-term
mmunological memory and autoimmune responses as potential
iomarkers of ageing (Almanzar et al., 2005; Kovaiou et al., 2007;
einberger et al., 2007; Herndler-Brandstetter et al., 2005).
In vitro, two types of senescence have been described. One
s telomere-dependent replicative senescence and the second is
tress-induced premature senescence (SIPS) (Sikora et al., 2014).
n view of previous results we hypothesised that during age-
ng, chronic antigenic load as well as oxidative stress may
ause decreased lymphocyte susceptibility to Damage-Induced Cell
eath (DICD) and, on the other hand, increased susceptibility to
ctivation-Induced Cell Death (AICD). As an intact equilibrium
etween survival and elimination of immune cells may  be deci-
ive for intact immune function and health we studied DICD and
ICD in T cells from donor samples (see Sikora et al., this issue).
The following research tasks have speciﬁcally been addressed:
Analysis of total IgG, IgE, IgM and IgA; serum/plasma concen-
trations of 14 cytokines; blood counts and differential blood
counts (performed by the recruiters locally); and phenotyping
of T cells, B cells NK cells and monocytes by immunoﬂuorescence
in proband samples.
Analysis of the number of sjTRECs; it was of particular interest to
analyse whether sjTREC concentrations differ in persons with and
without latent viral infections such as CMV, HHV-6 and HHV-7.
Analysis of antibodies and cellular immunity (IFN gamma  pro-
duction by Elispot) against measles and mumps  virus (typicallynd Development 151 (2015) 2–12
childhood exposure) in order to assess long-term immunological
memory.
• Analysis of antibodies and cellular immunity to highly con-
served proteins of the inﬂuenza virus (NP and M proteins) as
well as tetanus (an agent against which most adult persons are
vaccinated at regular intervals) in order to assess short-term
immunological memory.
• Analysis of immune responses against CMV, in order to assess the
effect of latent viral infection.
• Analysis of autoantibodies against thyroglobulin (as an exam-
ple of a tissue-speciﬁc antigen) and antinuclear antibodies (as
example for a systemic immune response).
• Analysis of susceptibility to Damage-Induced Cell Death (DICD)
and Activation-Induced Cell Death (AICD), respectively, by using
apoptosis markers.
3.5. WP  5: clinical chemistry, hormones and markers of
metabolism
In the literature a plethora of classical clinical chemistry param-
eters have been proposed as potential biomarkers of ageing.
Prominent examples are parameters of carbohydrate and lipid
metabolism or hormones. We  have selected the most promising
ones for inclusion in the MARK-AGE project and we have added sev-
eral new potential biomarkers related with metabolism that have
emerged in the recent work of some Partners (Al-Delaimy et al.,
2006; Rezzi et al., 2007a,b; Kochhar et al., 2006; Heijmans et al.,
2006; Mooijaart et al., 2006; Hurme et al., 2005, 2007; Rontu et al.,
2006; Lehtimaki et al., 2007).
The following candidate biomarkers have speciﬁcally been
addressed:
Systemic metabolism and toxicity parameters
• Blood urea nitrogen and creatinine, used for the evaluation of
renal function.
• Metal binding proteins including transferrin, ferritin, 2-
macroglobulin and ceruloplasmin, in order to complement metal
ion determinations (see below).
• Fasting glucose and fasting insulin as a measure for glucose
homeostasis, insulin resistance and diabetic conditions.
• Glycosylated hemoglobin (A1C) as a measure for the long-term
systemic glucose load, in order to detect (pre) diabetic conditions.
• Some basic/reference parameters, including albumin and serum
protein concentration.
Fatty acid and cholesterol metabolism parameters
• Fasting triglycerides and free fatty acids were measured to detect
metabolic disorders in lipid metabolism.
• Total cholesterol, HDL and LDL-cholesterol were measured
(together with triglycerides) for risk assessment of cardiovascular
diseases.
• Concentrations of lipoprotein particle size classes by NMR.
Systemic inﬂammation parameters
• C-reactive protein (CRP), homocystein, uric acid and ﬁbrinogen
are inﬂammatory markers associated cardiovascular disease and
hypertension.
• Serum amyloid A and P, and pentraxin 3 were amongst the acute
phase proteins studied.• Adiponectin is correlated with an anti-inﬂammatory state and
suppresses metabolic derangements that may  result in type II
diabetes, obesity, atherosclerosis and non-alcoholic fatty liver
disease.
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Additional candidate biomarkers
Testosterone, the principal male sex hormone whose levels are
known to decline gradually with age in males.
Prostate speciﬁc antigen (PSA) was measured for the detection of
(pre) neoplastic processes in the prostate and prostate cancer in
particular.
Vitamin D, a recently identiﬁed promising candidate related to
ageing and several chronic diseases, was also studied.
Dehydroepiandrosterone sulfate (DHEAS) is known to decline
with age and is a classical candidate biomarker of human ageing
(Lane et al., 1997).
Novel biomarkers to be derived from metabonomics analysis
Nuclear Magnetic Resonance (NMR)-based metabolic proﬁling
of serum/plasma samples and urine samples from probands.
NMR  proﬁles display a set of resonances arising from major low-
molecular weight molecules, such as ketone bodies, organic acids,
amino acids, and aromatic metabolites (Oostendorp et al., 2006;
Rezzi et al., 2007a,b; Ramadan et al., 2007)
.6. WP  6: oxidative stress markers
It has been postulated that oxidative stress is causal for the age-
ng process. Oxidative stress refers to an imbalance between ROS
ormation and antioxidant defence. In human beings large amounts
f oxidants are formed in various physiological metabolic reactions
nd even a wider variety of pathophysiological conditions. The body
s able to respond to such enhanced oxidant formation with com-
ensatory antioxidant reactions. These reactions are also complex
nd a large variety of different enzymes are involved. If antioxi-
ant protection is insufﬁcient, oxidative stress with an enhanced
ormation of oxidative stress markers occurs.
Oxidative damage accumulation in macromolecules has been
onsidered causative for cellular damage and pathology. Such dam-
ge seems to be closely related to the ageing process. Although
he relationship between oxidative damage and the ageing process
as been established in various model systems, only few studies
eported a systematic analysis of oxidative stress parameters in
ealthy humans related to age of individuals (Pandey and Rizvi,
010; Gil et al., 2006).
The purpose of this work package was to analyse a set of param-
ters of oxidative stress parameters (Gil et al., 2006), vitamins
nd trace elements (Mazzatti et al., 2007; Malavolta et al., 2006;
occhegiani et al., 2006) in human blood, serum, urine and buc-
al mucosa cells. Preference was given to new technologies for the
ssessment of oxidation markers and to markers already estab-
ished and suitable for adaptation to high-throughput formats.
The following candidate biomarkers have speciﬁcally been
ddressed:
Malondialdehyde.
Carbonylated and nitrated proteins.
Oxidation of LDL.
NO metabolic-pathway products (NOx)x .
Isoprostanes.
Cellular glutathione.
Vitamin content (-tocopherol, -carotene and ascorbate) of
serum and buccal mucosal cells.
Trace elements (Zn, Cu, Se and Fe) in blood/serum.nd Development 151 (2015) 2–12 7
3.7. WP  7: emergent biomarkers of ageing from model systems
and novel methodological approaches
Whilst conventional biomarkers of disease have been estab-
lished by hypothesis-driven approaches based on an underlying
knowledge of the disease process or serendipity, studies which
focus on identiﬁcation of biomarkers of healthy ageing are con-
strained in their ability to follow individuals over prolonged periods
of time until their chronological age deviates from their biological
age. To overcome this problem, we  adopted parallel, systematic
approaches to investigate putative biomarkers in speciﬁc ageing
cohorts (as deﬁned in WP1) alongside the study of models of accel-
erated ageing, such as progeroid syndromes (in humans and mice)
and induced senescence in leukocytes from subjects of different
ages. We  used both established and novel approaches to search for
biomarkers of ageing in an iterative process, where markers derived
from models would inform in vivo biomarker searches.
(a) Model Systems
Progeroid mouse models
Progeroid syndromes are rare disorders with premature ageing
and a shortened life expectancy. These conditions are character-
ized by extremely accelerated ageing, showing many hallmarks
of normal ageing including cessation of growth, liver, kidney and
bone abnormalities, retinopathy, hearing loss, sarcopenia, neu-
rodegeneration, sensitivity to UV light, and a premature aged
appearance due to kyphosis, baldness, loss of subcutaneous fat,
and dry wrinkled skin. Cockayne syndrome (CS), Hutchinson-
Gilford syndrome, Werner’s syndrome (WS), Bloom’s syndrome,
and trichothiodystrophy are all autosomal recessive disorders
with progeroid symptoms. Although some differences exist in the
pathology of these conditions it is striking that the causal fac-
tor of all these syndromes lies in impaired genome maintenance
due to DNA repair deﬁciencies or genome instability. One aim of
the project was  the identiﬁcation of biomarkers of ageing in CS,
a rare human disorder, in which patients suffer from segmen-
tal but bona ﬁde accelerated ageing. The mean age at death of
CS patients is 12.5 years. There is currently no treatment for CS
and related disorders available and the clinical management of
patients is purely supportive. CS is an autosomal recessive disorder
caused by mutations in the CSA or CSB genes, which are involved in
transcription-coupled nucleotide and base excision repair (TCER).
The TCER sub-pathway selectively removes lesions from the tran-
scribed strand that actually block transcription. As such this process
is important for promoting recovery of the vital process of tran-
scription and thus cellular survival from transcription-blocking
DNA lesions. One of the objectives of the project was to apply the
biomarkers studied in Work Packages 2 through 6 to progeroid
patients, thereby determining to which extent premature and nor-
mal  ageing resemble each other and their suitability to identify
ageing features independent of chronological age.
To understand the aetiology of CS and other DNA repair dis-
orders such as trichothiodystrophy (TTD) and the cancer-prone
condition xeroderma pigmentosum (XP), an extensive collection of
DNA repair-deﬁcient transgenic mice had previously been gener-
ated, many of which mimic  the hallmarks of the corresponding
human repair syndrome. These mice display either a strong can-
cer predisposition (XP-like) or many features of premature ageing,
or a combination. Although the Csbm/m mouse model reliably
reﬂects the repair defect and UV-sensitive phenotype of the patient,
animals show relatively mild growth retardation and neurological
abnormalities, accompanied by age-related retinal degeneration.
Interestingly, when TCER-defective Csbm/m mice were crossed
with completely NER-deﬁcient Xpa−/− animals double mutants
phenocopy human CS surprisingly well, including its age-related
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athology. Although Csbm/m/Xpa−/− pups are devoid of any overt
mbryonic developmental phenotype, they display severe post-
atal growth retardation, impaired psychomotor development,
taxia, progressive cachexia, and kyphosis. Loss of retinal pho-
oreceptors is also further accelerated, as compared to Csbm/m
nimals. Moreover, most Csbm/m/Xpa−/− newborns die during or
hortly after birth, whereas animals that survive birth stress do
ot survive beyond three weeks. Exploiting the genetic and envi-
onmentally fully deﬁned mouse system these and other mouse
utants for XP, XP/CS and TTD provided a convenient tool to
educe speciﬁc biomarkers in various organs/tissues including
erum. Within MARK-AGE a set of mouse biomarkers for ageing
as developed and evaluated, using transcriptomics, immuno-
istochemistry and serum/urine markers in prematurely ageing
ouse models with different life span and ageing-related pathol-
gy to deliver universal markers of ageing. Biological material from
enetically and environmentally controlled, (histo) pathologically
ell-deﬁned cohort studies with NER-deﬁcient mouse models,
erved to identify parameters that were expected report on the
iological age of the animals and/or the onset and progression of
geing-related pathology in various tissues (e.g. liver, brain) (van
er Pluijm et al., 2007; de Boer et al., 2002; Rossi et al., 2007;
iedernhofer et al., 2006).
Stress induced premature senescence
There are several pathways activating cellular senescence; these
nclude telomere uncapping, DNA damage, oxidative stress and
ncogene, amongst others (Ben-Porath and Weinberg, 2005). Nor-
al  human diploid ﬁbroblasts cultured in vitro irreversibly stop
ividing after a certain number of cumulative population doublings
n a process known as replicative senescence (Hayﬂick, 1965). This
imited proliferative life span has been observed in many other
ukaryotic cell types and has been interpreted as a manifestation
f cellular ageing. Random metabolic modiﬁcations appear within
hese cells over time, leading to random damage of the cellular com-
onents. These damaged cellular components are not completely
liminated or repaired and therefore accumulate with time and
rogressively impair cellular functions. Cellular senescence can be
lso regarded as a permanently maintained DNA damage response
tate (von Zglinicki et al., 2005). ROS are important contributors to
he ageing process and we have conﬁrmed the similarities between
eplicative senescence and stress induced premature senescence
SIPS) (Dumont et al., 2000; Dierick et al., 2002; Pascal et al.,
005). In MARK-AGE, we used SIPS to “age” T and B cells from
he subjects recruited in WP1  and searched for novel biomarkers
sing genomic array and proteomic approaches described below
Debacq-Chainiaux et al., 2005; Frippiat et al., 2001).
Novel methodological approaches
Analysis of miRNAs
MicroRNAs (miRNAs) are small, abundant non-coding RNA
olecules of about 21–23 nucleotides that have been shown to
ffect a broad spectrum of biological activities. Interestingly, there
s evidence that a remarkably large proportion of genes (>30%)
re subject to microRNA-mediated regulation. In general, miR-
As function post-transcriptionally by inhibiting translation from
peciﬁc target mRNAs. Up to now, about 600 miRNAs have been
haracterized in humans. These small RNA molecules were thought
o contribute to ageing of C. elegans. It has been previously shown
hat miRNA cause a general reduction of message-speciﬁc transla-
ional inhibition during ageing. Reducing the activity of a speciﬁc
iRNA lin-4 shortened life span and accelerated tissue aging,
hereas overexpressing lin-4 or reducing the activity of lin-14
xtended life span of C. elegans, frequently used as a model sys-
em for mammalian ageing (Boehm and Slack, 2005). Studies onnd Development 151 (2015) 2–12
miRNA expression levels in tissues of young and old mice showed
the differential and clearly tissue speciﬁc expression of some miR-
NAs (Smith-Vikos and Slack, 2012). On the level of cells, it was
also shown that such differential expression can directly inﬂu-
ence cellular ageing. miR-21 was found up-regulated by replicative
and stress-induced senescence in human endothelial cells. miR-
21 over-expression reduces the replicative lifespan, while stable
knock-down extends the replicative lifespan of these endothelial
cells (Dellago et al., 2013). On the organ level, it is clear that not
all miRNAs that are up- or down-regulated during ageing neces-
sarily play crucial roles during ageing. As no “key regulator” on
tissue ageing was  identiﬁed yet in mammalians, one has to clarify
which miRNAs are activated or repressed especially in degenera-
tive disease contexts and which are really associated with aging
per se. Therefore we  are evaluating miRNA expression as a “novel”
biomarker of ageing using the leukocytes of subjects recruited in
WP1.
Phage antibodies against novel markers of endothelial and T cell
ageing
The phage display antibody library technology has been found
to be a useful method to isolate antigen-speciﬁc antibody frag-
ments, since the repertoire of antibody speciﬁcities is broad and
since it bypasses the need of immunization. When applied as a
discovery tool, the phage display technology can be considered
a complementation to traditional proteomic approaches using 2-
D gel electrophoresis and mass spectrometry, which quite often
have problems in identifying proteins which are very hydrophobic
(Gonzalez-Dosal et al., 2006; Jensen et al., 2003). During ageing,
both in vivo and in vitro, changes in the proteomic proﬁle are
observed. By performing subtractive selection of recombinant anti-
bodies binding to e.g. endothelial cells allowed to age in vitro, where
young cultured endothelial cells is applied as competitor, antibod-
ies binding potential biomarkers of ageing can be obtained (Boisen
et al., 2010; Boisen and Kristensen, 2010)
Such approaches have enabled the development of a panel of
antibodies recognizing in vitro ageing human endothelial cells dur-
ing the previous EU project Proteomage, in particular the secretome
of endothelial cells. With age there is a decrease in the ability to
form new blood vessels, which is a biomarker of ageing. The pur-
pose of the work in the MARK-AGE project was to evaluate the
in vivo signiﬁcance of endothelial secretome biomarkers identi-
ﬁed from in vitro models for their in vivo relevance by screening
plasma from subjects recruited in WP1  for these markers. More
speciﬁcally it was  found that the intermediate ﬁlament protein,
vimentin, is found in the serum. As studies within the EU funded
project, Proteomage, established that extracellular vimentin can
exert functional changes to the ability to form new blood vessels, it
has been of particular interest to see if there is an age speciﬁc cor-
relation with the amount of vimentin in serum. This, in part, might
explain why  in general older people exhibit decreased ability to
form new blood vessels. Using a battery of antibodies raised against
endothelial progenitor cells, it was further proposed to evaluate
whether the number of endothelial progenitor cells in serum qual-
iﬁes as a biomarker of ageing (Bertelsen et al., 2014; Williamson
et al., 2012). This again could have implications for the generally
decreased ability of older subjects to form new blood vessels.
Microarray and proteomics
Genomics and proteomics offer the opportunity for an unbiased
systematic discovery route for novel biomarkers and are becom-
ing increasingly popular (Grifﬁths et al., 2002; Grifﬁths et al., 2006;
Aldred et al., 2006; Grant et al., 2007). Nevertheless, only few groups
have undertaken proteomic studies of either plasma proteins of
mononuclear cells in healthy human ageing. The ﬁrst of these,
published by Thambietty et al. in 2010, described a differential
plasma protein pattern between 57 older adults with and without
amyloid deposition in the brain (Thambisetty et al., 2010). Subse-
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uently, differential expression of ApoE and antioxidant proteins
as observed in the plasma of 10 Japanese supercentenarians com-
ared with 10 young people (Miura et al., 2011). In 2012, some of
s described alterations in transferrin glycosylation during healthy
geing (Dunston et al., 2012). The advantages of applying such an
pproach in the MARKAGE population is the greater power to evalu-
te the validity of novel biomarkers discovered through proteomics
hen compared with small sample size discovery programmes.
fter the completion of MARKAGE, one other study has analysed
y ELISA the levels of protein biomarkers that were not discovered
sing proteomics in plasma during healthy ageing in comparison
ith older adults that develop frailty syndromes. These authors
howed that higher levels of transferrin ﬁbrinogen and interleukin-
 were associated with frailty status and frailty score (Darvin et al.,
014).
Ever since the concept of MARK-AGE has been developed
icroarray has been used extensively to characterise ageing-
elated changes in gene expression. Indeed, the systematic analysis
f miR, single nucleotide polymorphisms and deep sequencing
pproaches have led to further insight into expression changes in
peciﬁc cell types (Laurie et al., 2012; Smigielska-Czepiel et al.,
014; van der Brug et al., 2010). The latter are by necessity
ross-sectional studies. The approach taken by MARK-AGE was to
nvestigate expression changes within unique accelerated mod-
ls of ageing the consortium had access to. Systematic microarray
nalysis of progeroid mutants has already yielded new potential
iomarkers: using full-genome microarray analysis some of us have
ecently identiﬁed a ‘survival’ response in the progeroid mouse
odels directed by down-regulation of the IGF1 somatotrophic
xis that boosts antioxidant defence, down-regulates metabolism
nd redirects energy resources from growth and development to
rotection, maintenance and repair. This adaptive switch aims to
low down ageing-related pathology and postpones death, thereby
romoting successful ageing. It is constitutively turned on in the
epair-compromised mouse mutants as a futile attempt to extend
ifespan and explains their dwarf phenotype. In normal mice the
ame principally beneﬁcial response can be transiently triggered
y chronic exposure to DNA-damaging agents and ROS-producing
ompounds. We  hypothesise that normal ageing is also associ-
ted with a similar response due to age-dependent accumulation
f damage. The existence of such a response allows predictions
or shifts in levels of speciﬁc proteins, activities, pathways and
etabolites that could serve as biomarkers. As the proteome is far
ore extensive than the transcriptome, it offers a richer source of
otential biomarkers but also poses increased problems in terms of
ynamic range, particularly in plasma. This is being addressed using
uality-assured subfractionation steps and restricted IPG range in
he ﬁrst dimension. In MARK-AGE, proteomics was to be adopted
n accordance with HUPO guidelines, in the search for biomark-
rs in plasma from subjects recruited in WP1, in CS/progeria and
n T and B cells subjected to SIPS in subjects recruited in WP1.
he identiﬁcation of putative markers was to be conﬁrmed by
equence analysis and their validation as biomarkers of ageing con-
rmed by alternative approaches such as ELISA where possible.
n view of the strong parallels between the mouse mutants and
he human syndromes, down-regulation of the IGF1 somatotrophic
xis biomarkers is likely to be instrumental for identiﬁcation of cor-
esponding markers in human patients and even normal ageing and
ill be evaluated in WP1  subjects.
.8. WP  8: data analysis and bioinformaticsIn view of the large amounts of clinical and biochemical data,
hich have been collected in the framework of the MARK-AGE
roject an appropriate and coherent strategy of data analysis and
odel building is mandatory.nd Development 151 (2015) 2–12 9
In order to extract a robust set of biomarkers of human ageing
and to derive a model for healthy ageing, the following tasks were
performed:
• Dataproperty analysis. Partial knowledge about suspected cor-
relations between measurements is available and being used
to judge the noise ratio within some of these measurements
using classical statistical techniques. We  also applied correlation
measures to identify additional relationships between measure-
ments. Repeated sampling, i.e. obtaining samples after 6 months
from 97 subjects, was  done to further investigate biological and
analytical variability in the measurements.
• Modelling. Both, statistical models as well as machine learn-
ing/data mining methods were to be used in order to build models
aiming to predict biological age from the available measure-
ments. We  used classical techniques, such as regression analysis
but also aim to introduce additional knowledge (monotonicity) to
improve those models. Neural Networks and Decision/Regression
Trees were to be used to ﬁnd more local relationships within the
data, for instance revealing properties that are relevant only for
a subset of the chosen population.
• Variance reduction. Through dimensionality reduction tech-
niques (principal component analysis and others) we aim at
reducing the number of required measurements while, at the
same time, reducing the variance in the predictions generated.
Machine Learning offers ensembles of models for this purpose,
which allows combining different, diverse predictors to generate
models with lower variance.
• Clustering/visualisation. We expect to discover previously
unknown or unexpected relationships in the data that deﬁne
successful ageing. Data visualisation techniques and interactive
methods such as visual clustering models may  help uncover some
of these relationships. It is expected that some measurements
will have higher correlations with the biological age than others
in parts of the population. Finding such clusters is further helping
reduce variance in the generated models since we will be able to
better model characteristics of subgroups.
3.9. WP  9 and WP  10
WP 9 and WP 10 were dedicated to dissemination, training,
project management (Fig. 1) and ethical issues.
4. Discussion
Biomarkers of human ageing are urgently needed for vari-
ety of reasons, including the identiﬁcation of individuals at high
risk of developing age-associated disease or disability. This would
prompt targeted follow-up examinations and, if available, pro-
phylactic intervention (e.g. changes in lifestyle) or early-stage
treatment of age-related disease. Furthermore, the availability of
powerful biomarkers would allow the assessment of the efﬁcacy
of forthcoming pharmacological and other interventions (including
optimisation of micronutrient intake and other dietary components
or physical activity) currently being developed with the aim to
lower the risk of age-associated disease even in individuals without
accelerated ageing.
In view of the rapidly increasing average life expectancy of
human beings world-wide, the prevalence of age-related diseases is
likely to increase as well. This necessitates effective new strategies
for prevention and early diagnosis of such conditions.It should be noted that different types of biomarkers have been
envisaged: (1) “neutral” markers of age (also called markers of
“chronological ageing”) possibly lacking the power of directly pre-
dicting disease risk, as the underlying physiological change may per
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e be harmless and without functional compromise; (2) markers
f (global) risk of age-related diseases. Those in category #2 are of
bvious and direct interest. Nevertheless, the usefulness of those in
ategory #1, especially as a combination of markers, should not be
ismissed, as they could reﬂect the rate of ageing that has prevailed
ver a certain time period in the past and the cumulative change it
as produced in the body. The detection of a previous faster-than-
ormal rate of ageing in a given individual should also be alarming
nd call for additional diagnostic and preventive measures.
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